Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Imatinib

Blood (2023) 142 (Supplement 1): 6367.

https://doi.org/10.1182/blood-2023-190780

Published: 2023

Journal Articles

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Blood (2023) 142 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2023-179043

Published: 2023

Journal Articles

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

Xiao-shuai Zhang, Bingcheng Liu, Jian Huang, Xin Du, Yanli Zhang, Na Xu, Xiaoli Liu, Li Weiming, Hai Lin, Huanling Zhu, Yunfan Yang, Ling Pan, Xiao-jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2023-185473

Published: 2023

Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Blood (2023) 142 (Supplement 1): 869.

https://doi.org/10.1182/blood-2023-187740

Published: 2023

Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Blood (2022) 140 (Supplement 1): 3891–3894.

https://doi.org/10.1182/blood-2022-168812

Published: 2022

Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Blood (2022) 140 (Supplement 1): 815–817.

https://doi.org/10.1182/blood-2022-166855

Published: 2022

Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 9647–9649.

https://doi.org/10.1182/blood-2022-164444

Published: 2022

Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Blood (2022) 140 (Supplement 1): 203–204.

https://doi.org/10.1182/blood-2022-170698

Published: 2022

Journal Articles

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 9620–9623.

https://doi.org/10.1182/blood-2022-166431

Published: 2022

Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Blood (2022) 140 (Supplement 1): 9637–9639.

https://doi.org/10.1182/blood-2022-168703

Published: 2022

Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Blood (2021) 138 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2021-153937

Published: 2021

Journal Articles

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-142142

Published: 2020

Journal Articles

Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution

Yunfan Yang, MD, Zhongqing Zou, MD, Ting Liu, MD PhD, Yongqian Jia, PhD, Ting Niu, MD PhD, Huanling Zhu, MD, Yu Wu, MD, Yuping Gong, MD, Hong Chang, MD, Jie Ji, MD, Jian Li, MD, Ling Pan

Blood (2019) 134 (Supplement_1): 5384.

https://doi.org/10.1182/blood-2019-128553

Published: 2019

Journal Articles

Preliminary Analysis Results of a Phase I Study of the FLT3 Inhibitor SKLB1028 in Patients with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Ting Liu, MD, Huanling Zhu, MD, Xuekun Yao, M.M., Yueying Peng, M.M., Yumei Wang, M.E., Guoning Zhan, B.E., Jing Yuan, M.S., Shaonan Ni, M.M., Jie Qiao, PhD, Zijian Hu, MD, Cheng Lyu, D.Eng.

Blood (2019) 134 (Supplement_1): 2654.

https://doi.org/10.1182/blood-2019-128472

Published: 2019

Journal Articles

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Jorge E. Cortes, MD, Qian Jiang, MD, Jianxiang Wang, MD, Jianyu Weng, MD, Huanling Zhu, MD, Liu Xiaoli, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Jerald Radich, MD, Michael R. Savona, MD, Patricia Martin Regueira, MD, Oumar Sy, PhD, Renuka Gurnani, BA, Giuseppe Saglio

Blood (2018) 132 (Supplement 1): 788.

https://doi.org/10.1182/blood-2018-99-111978

Published: 2018

Journal Articles

Retrospective Treatment Analysis of a Series of 104 Patients with Adult Onset Hemophagocytic Lymphohistiocytosis in a Single Institution of China

Blood (2016) 128 (22): 4882.

https://doi.org/10.1182/blood.V128.22.4882.4882

Published: 2016

Journal Articles

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

Blood (2015) 125 (18): 2771–2778.

https://doi.org/10.1182/blood-2014-09-601674

Published: 2015

Journal Articles

An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,

Yongqian Jia, MD, Bing Xiang, MD, Xiaodong Wang, MD, Jianjun Li, MD, Chuan He, MD, Yi Su, MD, Hong Lu, MD, Ting Niu, MD, Jie Huang, MD, Xinchuan Chen, MD, Xu Cui, MD, Yuping Gong, MD, PhD, Huanling Zhu, MD, Ting Liu, MD

Blood (2011) 118 (21): 3714.

https://doi.org/10.1182/blood.V118.21.3714.3714

Published: 2011

Journal Articles

Imatinib 400mg Daily Combined with Vindesine and Dexamethasone As Induction and Maintenance Therapy for Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Ting Liu, MD, Pu Kuang, MD, Tian Dong, MD, Bing Xiang, MD, Jianjun Li, MD, Xinchuan Chen, MD, Chuan He, MD, Hongbing Ma, MD, Jie Ji, MD, Yuping Gong, MD, PhD, Hong Chang, MD, Yu Wu, MD, PhD, Huanling Zhu, MD, Yuchun Wang, MD, PhD

Blood (2011) 118 (21): 4243.

https://doi.org/10.1182/blood.V118.21.4243.4243

Published: 2011

NARROW

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Imatinib

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution

Preliminary Analysis Results of a Phase I Study of the FLT3 Inhibitor SKLB1028 in Patients with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Retrospective Treatment Analysis of a Series of 104 Patients with Adult Onset Hemophagocytic Lymphohistiocytosis in a Single Institution of China

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,

Imatinib 400mg Daily Combined with Vindesine and Dexamethasone As Induction and Maintenance Therapy for Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only